Toxicological interactions involving psychiatric drugs and alcohol: An update

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 2, 2003, Pages 81-95

  Tanaka, Einosuke ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Antidepressants; Antipsychotics; Cytochrome P450; Drug drug interactions; Ethyl alcohol; Pharmacokinetics

Indexed keywords

ACEPROMAZINE; ALCOHOL; AMISULPRIDE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BROMPERIDOL; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOTIAPINE; CLOZAPINE; DESIPRAMINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TRIFLUPERIDOL; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGE; ALCOHOL CONSUMPTION; DIET; DISEASE COURSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENVIRONMENT; GASTROINTESTINAL ABSORPTION; GENDER; HUMAN; INTOXICATION; METABOLIC CLEARANCE RATE; REVIEW;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ETHANOL; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; POISONING;

EID: 0038670760     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00459.x     Document Type: Review

References (133)

1. National Research Institute of Police Science. Annual case reports of drug and toxic poisoning in Japan (1990-2001), no. 33-43. (in Japanese).
2. Scott DB, Fagan D, Tiplady B. (1982) Effects of amitriptyline and zimelidine in combination with ethanol. Psychopharmacology (Berl), 76, 209-211.
3. Dorian P, Sellers EM, Reed KL, Warsh JJ, Hamilton C, Kaplan HL, Fan T. (1983) Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. European Journal of Clinical Pharmacology, 25, 325-331.
4. Warrington SJ, Ankier SI, Turner P. (1984) An evaluation of possible interactions between ethanol and trazodone or amitriptyline. British Journal of Clinical Pharmacology, 18, 549-557.
5. Warrington SJ, Ankier SI, Turner P. (1986) Evaluation of possible interactions between ethanol and trazodone or amitriptyline. Neuropsychobiology, 15(Suppl. 1), 31-37.
6. Salvadori C, Ward C, Defrance R, Hopkins R. (1990) The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans-influence of alcohol co-administration. Fundamental & Clinical Pharmacology, 4, 115-125.
7. van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A. (1992) Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clinical Pharmacology and Therapeutics, 52, 427-435.
8. Forrest FM, Forrest IS, Finkle BS. (1972) Alcohol-chlorpromazine interaction in psychiatric patients. Agressologie, 13, 67-74.
9. Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA. (1982) Imipramine disposition in alcoholics. Journal of Clinical Psychopharmacology, 2, 2-7.
10. Sandoz M, Vandel S, Vandel B, Bonin B, Allers G, Volmat R. (1983) Biotransformation of amitriptyline in alcoholic depressive patients. European Journal of Clinical Pharmacology, 24, 615-621.
11. Ciraulo DA, Barnhill JG, Jaffe JH. (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clinical Pharmacology and Therapeutics, 43, 509-518.
12. Linnoila M, Mattila MJ, Kitchell BS. (1979) Drug interactions with alcohol. Drugs, 18, 299-311.
13. Lane EA, Guthrie S, Linnoila M. (1985) Effects of ethanol on drug and metabolite pharmacokinetics. Clinical Pharmacokinetics, 10, 228-247.
14. Weller RA, Preskorn SH. (1984) Psychotropic drugs and alcohol: pharmacokinetic and pharmacodynamic interactions. Psychosomatics, 25, 301-303, 305-306, 309.
15. Shoaf SE, Linnoila M. (1991) Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacological Bulletin, 27, 577-594.
16. Tanaka E, Misawa S. (1998) Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants - an update. Journal of Clinical Pharmacology and Therapeutics, 23, 331-336.
17. Tanaka E, Misawa S. (1999) Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. Journal of Clinical Pharmacology and Therapeutics, 24, 7-16.
18. Shen WW, Lin KM. (1991) Cytochrome P-450 monooxygenases and interactions of psychotropic drugs. International Journal of Psychiatry in Medicine, 21, 47-56.
19. Shen WW. (1995) Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. International Journal of Psychiatry in Medicine, 25, 277-290.
20. Ketter TA, Flockhart DA, Post RM et al. (1995) The emerging role of cytochrome P450, 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
21. Taylor D, Lader M. (1996) Cytochromes and psychotropic drug interactions. British Journal of Psychiatry, 168, 529-532.
22. Brosen K. (1996) Are pharmacokinetic drug interactions with the SSRIs an issue? International Clinical Psychopharmacology, 11(Suppl. 1), 23-27.
23. Preskorn SH. (1996) Reducing the risk of drug-drug interactions: a goal of rational drug development. Journal of Clinical Psychiatry, 57(Suppl. 1), 3-6.
24. Ereshefsky L. (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry, 57(Suppl. 11), 12-25.
25. Ereshefsky L, Riesenman C, Lam YW. (1996) Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Journal of Clinical Psychiatry, 57(Suppl. 8), 17-24.
26. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics, 33, 454-471.
27. Virani A, Mailis A, Shapiro LE, Shear NH. (1997) Drug interactions in human neuropathic pain pharmacotherapy. Pain, 73, 3-13.
28. Fang J, Gorrod JW. (1999) Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Molecular Neurobiology, 19, 491-510.
29. Coutts RT, Urichuk LJ. (1999) Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Molecular Neurobiology, 19, 325-354.
30. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. (1999) Metabolism of some 'second'- and 'fourth'-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Molecular Neurobiology, 19, 427-442.
31. Monaco F, Cicolin A. (1999) Interactions between anticonvulsant and psychoactive drugs. Epilepsia, 40(Suppl. 10), S71-S76.
32. Prior TI, Chue PS, Tibbo P, Baker GB. (1999) Drug metabolism and atypical antipsychotics. European Neuropsychopharmacology, 9, 301-309.
33. Poolsup N, Li Wan Po A, Knight TL. (2000) Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacology and Therapeutics, 25, 197-220.
34. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594-598.
35. Xiao ZS, Goldstein JA, Xie HG et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics, 281, 604-609.
36. Ferguson RJ, De Morais SM, Benhamou S et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. Journal of Pharmacological Experimental Therapy, 284, 356-361.
37. Tanaka E. (1999) Update: genetic polymorphism of drug metabolizing enzymes in humans. Journal of Clinical Pharmcology and Therapeutics, 24, 323-329.
38. Bertilsson L, Dahl ML, Sjoqvist F et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet, 341, 63.
39. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences of the USA, 90, 11 825-11 829.
40. Meyer JW, Woggon B, Baumann P, Meyer UA. (1990) Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. European Journal of Clinical Pharmacology, 39, 613-614.
41. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl), 114, 53-62.
42. Dahl SG. (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Therapeutic Drug Monitoring, 4, 33-40.
43. Wode-Helgodt B, Alfredsson G. (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berl), 73, 55-62.
44. Dahl SG, Hall H. (1981) Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology (Berl), 74, 101-104.
45. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ. (1991) Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. American Journal of Psychiatry, 148, 790-792.
46. Daniel DG, Randolph C, Jaskiw G et al. (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. Journal of Clinical Psychopharmacology, 14, 340-343.
47. Inaba T, Jurima M, Mahon WA, Kalow W. (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin P-hydroxylase and sparteine monooxygenase. Drug Metabolism and Disposition, 13, 443-448.
48. Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM, Burch NR, Bowden CL. (1985) Effects of carbamazepine on plasma haloperidol levels. Journal of Clinical Psychopharmacology, 5, 106-109.
49. Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y. (1995) The drug-drug interaction effects of haloperidol on plasma carbamazepine levels. Clinical Neuropharmacology, 18, 233-236.
50. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics, 7, 415-418.
51. Warner M, Kohler C, Hansson T, Gustafsson JA. (1988) Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. Journal of Neurochemistry, 50, 1057-1065.
52. Schilter B, Omiecinski CJ. (1993) Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain. Molecular Pharmacology, 44, 990-996.
53. Weathermon R, Crabb DW. (1999) Alcohol and medication interactions. Alcohol Research Health, 23, 40-54.
54. Sellers EM, Holloway MR. (1978) Drug kinetics and alcohol ingestion. Clinical Pharmacokinetics, 3, 440-452.
55. Watanabe M, Tateishi T, Tanaka M, Kumai T, Kobayashi S. (1999) Role of CYP3A in bromperidol metabolism in rat in vitro and in vivo. Xenobiotica, 29, 839-846.
56. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K. (2000) Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Science, 67, 175-184.
57. Shin JG, Soukhova N, Flockhart DA. (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metabolism and Disposition, 27, 1078-1084.
58. Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK. (1999) Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chemico-biological Interactions, 118, 171-189.
59. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. (1996) In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology, 41, 181-186.
60. Ring BJ, Catlow J, Lindsay TJ et al. (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics, 276, 658-666.
61. Marsh JC, Chowdry J, Parry-Jones N, Ellis SW, Muir KR, Gordon-Smith EC, Tucker GT. (1999) Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia. British Journal of Haematology, 104, 266-270.
62. Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. (2000) Identification of the major human liver cytochrome P450 isoform (s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. British Journal of Clinical Pharmacology, 49(Suppl. 1), 35S-42S.
63. Shiraga T, Kaneko H, Iwasaki K, Tozuka Z, Suzuki A, Hata T. (1999) Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica, 29, 217-229.
64. Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, Sjoqvist F. (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clinical Pharmacology and Therapeutics, 59, 423-428.
65. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT. (1997) Cytochromes P450 mediating the N-demethylation of amitriptyline. British Journal of Clinical Pharmacology, 43, 137-144.
66. Coutts RT, Bach MV, Baker GB. (1997) Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. Xenobiotica, 27, 33-47.
67. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. (1998) Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. Journal of Clinical Pharmacology, 38, 112-121.
68. Haffen E, Vandel P, Broly F, Vandel S, Sechter D, Bizouard P, Bechtel PR. (1999) Citalopram: an interaction Study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry, 32, 232-234.
69. Olesen OV, Linnet K. (1999) Studies on the stereo-selective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology, 59, 298-309.
70. Nielsen KK, Flinois JP, Beaune P, Brosen K. (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. Journal of Pharmacology and Experimental Therapeutics, 277, 1659-1664.
71. Wu ZL, Huang SL, Ou-Yang DS, Xu ZH, Xie HG, Zhou HH. (1998) Clomipramine N-demethylation metabolism in human liver microsomes. Zhongguo Yao Li Xue Bao, 19, 433-436.
72. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI. (1998) Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. Journal of Pharmaceutical Sciences, 87, 1184-1189.
73. Ball SE, Ahern D, Scatina J, Kao J. (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology, 43, 619-626.
74. von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI. (1998) Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. Journal of Pharmaceutical Sciences, 87, 1184-1189.
75. Haritos VS, Ghabrial H, Ahokas JT, Ching MS. (2000) Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics, 10, 591-603.
76. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. (2000) (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metabolism and Disposition, 28, 1187-1191.
77. Cheer SM, Goa KL. (2001) Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs, 61, 81-110.
78. Damkier P, Hansen LL, Brosen K. (1999) Effect of fluvoxamine on the pharmacokinetics of quinidine. European Journal of Clinical Pharmacology, 55, 451-456.
79. Kusumoto M, Ueno K, Oda A et al. (2001) Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. Clinical Pharmacology and Therapeutics, 69, 104-107.
80. Madsen H, Rasmussen BB, Brosen K. (1997) Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clinical Pharmacology and Therapeutics, 61, 319-324.
81. Ball SE, Ahern D, Scatina J, Kao J. (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology, 43, 619-626.
82. Firkusny L, Gleiter CH. (1994) Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. British Journal of Clinical Pharmacology, 37, 383-388.
83. Chow T, Hiroi T, Imaoka S, Chiba K, Funae Y. (1999) Isoform-selective metabolism of mianserin by cytochrome P-450 2D. Drug Metabolism and Disposition, 27, 1200-1204.
84. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metabolism and Disposition, 28, 1168-1175.
85. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. (1995) Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel Study. Clinical Pharmacology and Therapeutics, 57, 670-677.
86. Olesen OV, Linnet K. (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metabolism and Disposition, 25, 740-744.
87. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (1999) Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. Journal of Clinical Pharmacology, 39, 567-577.
88. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Karlow W. (1998) Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. Journal of Clinical Psychopharmacology, 18, 198-207.
89. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover Study: intraindividual variability and plasma concentration correlations. Journal of Clinical Pharmacology, 40, 58-66.
90. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. (1998) Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. Journal of Pharmacology and Experimental Therapeutics, 285, 428-437.
91. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. (2000) In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biological Psychiatry, 47, 655-661.
92. Bolaji OO, Coutts RT, Baker GB. (1993) Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Research Communications Chemistry Pathological Pharmacology, 82, 111-120.
93. Rejent TA, Doyle RE. (1982) Maprotiline fatality: case report and analytical determinations. Journal of Analytical Toxicology, 6, 199-201.
94. Meatherall RC, Guay DR, Chalmers JL, Keenan JR. (1983) A fatal overdose with clomipramine. Journal of Analytical Toxicology, 7, 168-171.
95. Meatherall RC, Guay DR, Nokes JM, Keenan JR. (1983) Toxicological findings in a death resulting from the ingestion of trimipramine. Journal of Forensic Science, 28, 1023-1029.
96. Fraser AD, Isner AF, Moss MA. (1986) A fatality involving clomipramine. Journal of Forensic Science, 31, 762-767.
97. Fraser AD, Susnik E, Isner AF. (1987) Analysis of 2-hydroxyimipramine in an imipramine-related fatality. Journal of Forensic Science, 32, 543-549.
98. Fraser AD, Isner AF. (1987) A carpipramine related fatality. Journal of Forensic Science, 32, 1103-1108.
99. Fraser AD, Isner AF, Perry RA. (1987) Distribution of trimipramine and its major metabolites in a fatal overdose case. Journal of Analytical Toxicology, 11, 168-170.
100. Hansson RC. (1990) A fatal case involving phenelzine and amitriptyline. TIAFT Bulletin, 20, 14-17.
101. Dawling S, Robinsons AJ. (1990) A fatal case involving benzhexol and amitriptyline. TIAFT Bulletin, 20, 20-22.
102. Ramcharitar V, Levine BS, Goldberger BA, Caplan YH. (1992) Bupropion and alcohol fatal intoxication: case report. Forensic Science International, 56, 151-156.
103. Rohrig TP, Ray NG. (1992) Tissue distribution of bupropion in a fatal overdose. Journal of Analytical Toxicology, 16, 343-345.
104. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet, 342, 1419.
105. McIntyre IM, King CV, Cordner SM, Drummer OH. (1994) Postmortem clomipramine: therapeutic or toxic concentrations? Journal of Forensic Science, 39, 486-493.
106. Dunn WA, Lockrey LA, McCain MW, Siek TJ. (1994) A report of a suicide involving digoxin and doxepin. Journal of Analytical Toxicology, 18, 122-123.
107. Romano G, Di Bono G. (1994) A fatality involving clothiapine and clomipramine. Journal of Forensic Science, 39, 877-882.
108. Logan BK, Friel PN, Case GA. (1994) Analysis of sertraline (Zoloft) and its major metabolite in post-mortem specimens by gas and liquid chromatography. Journal of Analytical Toxicology, 18, 139-142.
109. Levine B, Jenkins AJ, Smialek JE. (1994) Distribution of sertraline in postmortem cases. Journal of Analytical Toxicology, 18, 272-274.
110. Ostrom M, Eriksson A, Thorson J, Spigset O. (1996) Fatal overdose with citalopram. Lancet, 348, 339-340.
111. Camaris C, Little D. (1997) A fatality due to moclobemide. Journal of Forensic Science, 42, 954-955.
112. Preskorn SH, Baker B. (1997) Fatality associated with combined fluoxetine-amitriptyline therapy. Journal of the American Medical Association, 277, 1682.
113. McIntyre IM, King CV, Staikos V, Gall J, Drummer OH. (1997) A fatality involving moclobemide, sertraline, and pimozide. Journal of Forensic Science, 42, 951-953.
114. Kudo K, Imamura T, Jitsufuchi N, Zhang XX, Tokunaga H, Nagata T. (1997) Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Forensic Science International, 86, 35-41.
115. Milner DA, Hall M, Davis GG, Brissie RM, Robinson CA. (1998) Fatal multiple drug intoxication following acute sertraline use. Journal of Analytical Toxicology, 22, 545-548.
116. Vermeulen T. (1998) Distribution of paroxetine in three postmortem cases. Journal of Analytical Toxicology, 22, 541-544.
117. Musshoff F, Schmidt P, Madea B. (1999) Fatality caused by a combined trimipramine-citalopram intoxication. Forensic Science International, 106, 125-131.
118. Segerberg-Konttinen M, Vuori E, Lukkari I, Penttila A. (1989) Fatal intoxication by Remoxipride. Journal of Forensic Science, 34, 500-503.
119. Duffield AD, Kemmenoe Av. (1990) A fatality involving theophyline and sulpiride. TIAFT Bulletin, 20, 9-12.
120. Tracqui A, Kintz P, Mangin P. (1993) A fatality involving two unusual compounds-zolpidem and acepromazine. American Journal of Forensic Medical Pathology, 14, 309-312.
121. Tracqui A, Kintz P, Jamey C, Mangin P. (1993) Toxicological data in a fatality involving cyamemazine. Journal of Analytical Toxicology, 17, 386-388.
122. Kintz P, Tracqui A, Parent X, Hanser E, Mangin P. (1994) Fatal sulpiride intoxication. TIAFT Bulletin, 24, 37-39.
123. Jitsufuchi N, Nagata T, Kudo K, Imamura T, Tokunaga H. (1995) Death due to asphyzia linked to antipsychotic drugs. Japanese Journal of Legal Medicine, 49, 255-259.
124. Springfield AC, Bodiford E. (1996) An overdose of risperidone. Journal of Analytical Toxicology, 20, 202-203.
125. Elian AA. (1998) Fatal overdose of olanzepine. Forensic Science International, 91, 231-235.
126. Stephens BG, Coleman DE, Baselt RC. (1998) Olanzapine-related fatality. Journal of Forensic Science, 43, 1252-1253.
127. Jenkins AJ, Sarconi KM, Raaf HN. (1998) Determination of olanzapine in a postmortem case. Journal of Analytical Toxicology, 22, 605-609.
128. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. (1998) A fatal drug interaction between clozapine and fluoxetine. Journal of Forensic Science, 43, 1082-1085.
129. Hino Y, Ikeda N, Kudo K, Tsuji A, Sannohe S. (1999) Death attributed to amobarbital and levomepromazine intoxication. Legal Medicine, 1, 48-51.
130. Levine B, Jenkins A, Chute D, Smialek JE. (1999) Perphenazine distribution in a postmortem case. Journal of Analytical Toxicology, 23, 127-129.
131. Rop PP, Sournac MH, Elie I, Burle J, Fornaris M. (1999) Toxicological analysis of sulpiride in a lethal poisoning case. Journal of Analytical Toxicology, 23, 294-296.
132. Stein S, Schmoldt A, Schulz M. (2000) Fatal intoxication with melperone. Forensic Science International, 113, 409-413.
133. Harrison D, Elliott S. (2001) A novel case of fatal pimozide poisoning. TIAFT Bulletin, 31, 11-13.